Literatur
-
1
Ludwig J, Viggiano T R, McGill D B. et al .
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc.
1980;
55
434-438
-
2
Angulo P.
Nonalcoholic fatty liver disease.
N Engl J Med.
2002;
346
1221-1231
-
3
Bianchi G, Marchesini G, Marzocchi R. et al .
Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression.
Liver Transpl.
2008;
14
1648-1654
-
4
Malik S M, deVera M E, Fontes P. et al .
Outcome after liver transplantation for NASH cirrhosis.
Am J Transplant.
2009;
9
782-793
-
5
Contos M J, Cales W, Sterling R K. et al .
Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.
Liver Transpl.
2001;
7
363-373
-
6
Kim W R, Poterucha J J, Porayko M K. et al .
Recurrence of nonalcoholic steatohepatitis following liver transplantation.
Transplantation.
1996;
62
1802-1805
-
7
Briceno J, Ciria R, Pleguezuelo M. et al .
Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
Liver Transpl.
2009;
15
37-48
-
8
Jonsson J R, Barrie H D, O’Rourke P. et al .
Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C.
Hepatology.
2008;
48
80-87
-
9
Kita Y, Mizukoshi E, Takamura T. et al .
Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus.
Metabolism.
2007;
56
1682-1688
-
10
Burra P.
Hepatitis C.
Semin Liver Dis.
2009;
29
53-65
-
11
Neef M, Ledermann M, Saegesser H. et al .
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.
J Hepatol.
2006;
45
786-796
-
12
Biecker E, De Gottardi A, Neef M. et al .
Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.
J Pharmacol Exp Ther.
2005;
313
952-961
-
13
Romeo S, Kozlitina J, Xing C. et al .
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
Nat Genet.
2008;
40
1461-1465
-
14
Weiskirchen R, Wasmuth H E.
The genes that underlie fatty liver disease: the harvest has begun.
Hepatology.
2009;
49
692-694
PD Dr. med. Claus Hellerbrand
Klinikum der Universität Regensburg
Klinik und Poliklinik für Innere Medizin I
Franz-Josef-Strauß-Allee 11
93042 Regensburg
Email: claus.hellerbrand@klinik.uni-regensburg.de
